Drug Repositioning Pipeline

About DeepLife

DeepLife, founded in 2019 in Paris, is a private, pre-revenue biotech company pioneering a causal AI platform to build digital twins of cells. The platform uses multi-omics data to simulate disease at the single-cell level, aiming to drastically reduce target discovery timelines and improve the low success rates of traditional drug development. With a highly educated team of around 25 employees, the company is developing its own internal pipeline while likely seeking platform partnerships with larger pharmaceutical firms.